Substance briefing: MPPP

Transcription

1 Substance briefing: MPPP This technical folder provides information on MPPP. The information provided is based on a number of existing data sources and work undertaken as part of the I-TREND project. Research informing the folder includes an analysis of user discussions on popular (insert country name) drug forums, an analysis of marketing on popular (insert country name: e.g. English speaking) web shops selling the substance, and scientific laboratory analysis of the compound through test purchasing of the substance from (insert country name) web shops. 1 Substance name(s) 1.1 Chemical name: Desmethylprodine 1.2 Popular/street/slangname(s): Users on Czech forums do not have a slang/street/ popular name for this substance 1.3 Other name(s): 1-methyl-4-phenyl-4-propionoxypiperidine, (1-Methyl-4- phenylpiperidin-4-yl) propanoate 1.4 Branded products in which the substance was found following analysis: 1.5 Branded products advertised as containing the substance on web shops: Ibiza, ziplock, El Magico, Fresh and Funky Czech web shop analysis did not find any web shop advertised branded products as containing MPPP substance. 1.6 Branded products discussed as containing the substance on drug forums: No branded products were discussed as containing MPPP 2. Classification and effect 1

2 2.1 Classification and effect confirmed through substance analysis Cathinones 2.2 Classification and effect referred to by users of drug forums Not discussed at Czech forums. 2.3 Classification and effect used in the marketing of the product on web shops Phenethylamine Cathinones Piperazine Tryptamines Cannabinoids Opioids Aminocyclohexanes Aminoindanes Arylalkylamines Benzodiazepines Piperidines and pyrrolidines Other NB: See reference list for sources related to classification (e.g. pharmacological studies, case studies, etc ) 3 Potential risks associated with use of the substance 3.1 General risks associated with the substance: pyrrolidinophenone derivates are expected to have a similar toxicological and pharmacological properties to those of pyrovalerone (4 -methyl-α-pyrrolidinovalerophenone) because of their close structural relation to this drug = suspected risks including life-threatening serotonin syndrome, hepatotoxicity, neurotoxicity, and psychopathology (??) 3.2 Users point of view on the substance and risk perception: MPPP was not discussed on Czech forums, therefore risk perception of users could not be assumed from this source. 4 Legal status and identification of the substance 4.1 Legal status/acts/laws in Czech Republic. MPPP is not 2

3 controlled in Czech Republic. 4.2 List of first identification and reporting to the EMCDDA by a national Reitox Focal Points Country Czech Republic Dates 0,75 g seizure 5 Photographs of the substance 5.1 Photograph of the substance purchased for laboratory analysis: 5.2 Photo/Printscreen of the product from the webshop: 6 Chemistry 6.1 Chemical Abstracts Service (CAS) registry number: Chemical information: MPPP is a new designer drug with assumed amphetamine-like effects. 6.2 Structure (picture of structural formula) 6.3 Molecular mass g/mol 6.4 Structural comparison with a related substance "4'-methyl-alpha-pyrrolidinopropiophenone = 4 -methyl-α- PPP = assumed amphetamine-like effects ATTENTION!! The acronym MPPP is also used for an unrelated narcotic analgesic 3

4 substance. " 6.5 (Insert pictures of developed formula of this original substance) 7 Analytical composition: results of substance analysis carried out from the sample purchased online. 7.1 Details of laboratory analysis technique used: Mean (%) = (sd.=.) (N sample analysed) Webshop Country (IP address) Country (packag e origin) For m Substance named on package/we bshop Confirm ed substanc es 1 benzofury 6 APB 1 Mephedrone 2 2 Mephedr one 7.2 Details of laboratory analysis technique used: 7.3 Substance marketing details Powder Euros minimum price per gram maximum price per gram mode price per gram mean price per gram 8 Price and marketing strategies on Czech web shops selling the substance Description of availability and marketing strategies on Czech 4

5 web shops selling the substance: The MDPBP was not find ( ) in any web shop Type of Czech websites selling the product No of shops ( ) RC shops 0 Commercial shops 0 Other Number of webshops available for Czech Republic with supposed country of origin in the EU selling the products No of web shops CZ address or phone number on web sites 0 Web shops with CZ IP code 0 Web shops with supposed country of origin in the EU Law enforcement and health data 9.1 Number of law enforcement seizures in Czech Republic in 2013/2014. In 2013 there was seizure 1/6609,25 g reported in Czech Republic and for year 2014 there are no seizures. 9.2 EMCDDA health alerts in Czech Republic. EMCDDA health alerts were none in Czech Republic. 1 The total number of web shops selling new synthetic drugs for CZ ( ) was 33. (For detail information about methodology of monitoring and selecting the web shops see methodology on trend.eu/). For the marketing analysis we chose 15% of the most popular web shops from CZ list of shops.the shops without prices for products and shops which provide just bulk/wholesale order were removed from our selection. In addition another 6 web shops, previously chosen for the purchase of substances, were added to the marketing analysis. The final number of web shops used for analysis was 11. For latter analysis, we use only shops where product was available. 2 Including web shops with CZ address or phone number on web sites 5

6 9.2 Confirmed deaths and acute cases reported in Czech Republic. 1 confirmed acute case were reported in 2013 from Czech Republic. 10 User experiences of the substance: results from an analysis of discussions Czech Drug Forums Methodological comment: The information below is based on an analysis of 0 drug forums,0 forum posts and 0 forum users Dosage specified by drug forum users (n = number of quotations) Initial Dosing: There was no discussion on initial dose (n= 0 ) Boosting: There was no discussion on boosting dose (n= 0 ) Threshold: There was no discussion on threshold dose (n= 0) Light: There was no discussion on light dose (n= 0) Common: There was no discussion on common dose (n= 0 ) Strong :There was no discussion on strong dose (n= 0) 10.2 Duration Onset: There was no discussion on onset time (n =0) Coming up: There was no discussion on coming up(n =0) Plateau: There was no discussion on plateau (n =0) Coming down: There was no discussion on coming down (n =0) After effects: There was no discussion on plateau (n =0) Hangover/Day after : There was no discussion on hangover (n =0) 10.3 Effects reported by forum users (n = 1) Physical effects Psychological effects Sought/expected 6

7 Desired Undesired 10.4 Tolerance Tolerance was not discussed in Czech drug forums Route of administration (n =0) Ingestion: This ROA of MPPP was not mentioned in Snorting: This ROA of MPPP was not mentioned in Czech drug forums (n =0) Rectal: This ROA of MPPP was not mentioned in Czech drug forums (n =0) Inhalation or insufflation: This ROA of MPPP was not mentioned in 10.6 Others substances referred to in discussion about MPPP Referred to in comparing the effects : Not mentioned on Referred to as increasing the effects: Not mentioned on Referred to in managing come down: Not mentioned on Other substance discussed in the same episode/combo: Not mentioned on Referred to as an agonist/ antagonist : Not mentioned on 10.7 Appearance and preparation (n =0) Not mentioned on 10.8 Patterns of use/frequency of use Not mentioned on 7

8 10.9 Context of consumption o Not mentioned on User's views and experiences on the online market o Not mentioned on Harm reduction Message o Not mentioned on User profile Effects, experiences and dosages of MPPP were not discussed. 11 Useful resources and literature 8